Publications

  • Salomé, B., Sfakianos, J. P., Ranti, D., Daza, J., Bieber, C., Charap, A., Hammer, C., Banchereau, R., Farkas, A. M., Ruan, D. F., Izadmehr, S., Geanon, D., Kelly, G., de Real, R. M., Lee, B., Beaumont, K. G., Shroff, S., Wang, Y. A., Wang, Y. C., Thin, T. H., … Horowitz, A. (2022). NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer cell40(9), 1027–1043.e9.
  • Hobbs, G., Cimen Bozkus, C., Moshier, E., Dougherty, M., Bar-Natan, M., Sandy, L., Johnson, K., Foster, J. E., Som, T., Macrae, M., Marble, H., Salama, M., El Jamal, S. M., Zubizarreta, N., Wadleigh, M., Stone, R., Bhardwaj, N., Iancu-Rubin, C., & Mascarenhas, J. (2021). PD-1 inhibition in advanced myeloproliferative neoplasms. Blood advances5(23), 5086–5097.
  • Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021). Therapeutic cancer vaccinesNature reviews. Cancer21(6), 360–378.